At the National Policy and Advocacy Summit on Biologics and Biosimilars, held in Washington, DC, on April 17, Earl “Buddy” Carter, Republican Congressman for Georgia’s first legislative district, highlighted his work to control the price of drugs for patients.
At the National Policy and Advocacy Summit on Biologics and Biosimilars, held in Washington, DC, on April 17, Earl “Buddy” Carter, Republican Congressman for Georgia’s first legislative district, highlighted his work to control the price of drugs for patients.
Carter discussed a piece of legislation that he is sponsoring: HR 5343, or the Prescription Transparency Act of 2018, which was introduced to the House of Representatives on March 20, 2018. The bill seeks to amend the Public Health Service Act to nullify pharmacy benefit managers’ (PBMs’) contractual provisions that prohibit pharmacists from telling consumers whether they could save money by paying for a prescription in cash rather than through their insurance plans.
Carter, a pharmacist himself, took PBMs to task for such provisions, which he termed “gag clauses.”
“We’re subject to penalties or being kicked out of the network” for telling patients about ways to save on their prescriptions. “Now how absurd is that? My legislation says that gag clauses will no longer be valid. It’s as simple as that,” said Carter.
He added that he is skeptical of PBMs in general: “I’m not against anybody making money…however, you cannot show me, and you cannot convince me…that [PBMs] bringing any value whatsoever to the system…if you talk to a PBM, and you ask what their mission is…[they would say that it is] to control prescription drug prices. Well, how is that working out for you?”
Carter emphasized the fact that the high cost of drugs is a nonpartisan problem that affects all Americans, and that innovative therapies, like high-cost drugs that target hepatitis C, are only useful to patients if they can afford them.
To that end, Carter says, biosimilars represent a critical opportunity for the US healthcare system to make drugs more accessible for patients who need them. For over 30 years in his pharmacy, Carter said, he would have patients come to his counter in tears because they couldn’t afford their medication, and biosimilars offer an important option for creating in price competition to bring down costs and increase access, which Carter called “the best thing we can do for our healthcare system.”
“[Biosimilars are] the wave of the future, and we understand that in pharmacy,” said Carter. “I’m all in.”
Carter also encouraged healthcare providers to engage with their representatives and raise awareness of the issues that impact individual practices. He urged practitioners to invite their congressional representatives to their practice settings to let them see the value of their work and the challenges they face in delivering care.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.